Design of Agglomerated Crystals of Ibuprofen During Crystallization: Influence of Surfactant

Document Type : Original Article


1 Drug applied Research Center, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

2 School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran


Ibuprofen is a problematic drug in tableting, and dissolution due to its poor solubility, hydrophobicity, and tendency to stick to surface. Because of the bad compaction behavior ibuprofen has to be granulated usually before tableting. However, it would be more satisfactory to obtain directly during the crystallization step crystalline particles that can be directly compressed and quickly dissolved.
Materials and Methods
Crystallization of ibuprofen was carried out using the quasi emulsion solvent diffusion method in presence of surfactant (sodium lauryl sulfate (SLS), Tween 80). The particles were characterized by differential scanning calorimetry (DSC), powder X-ray diffraction (XRPD) and were evaluated for particle size, flowability, drug release and tableting behavior.
Ibuprofen particles obtained in the presence of surfactants consisted of numerous plate- shaped crystals which had agglomerated together as near spherical shape. The obtained agglomerates exhibited significantly improved micromeritic properties as well as tableting behavior than untreated drug crystals. The agglomerates size and size distribution was largely controlled by surfactant concentration, but there was no significant influence found on the tableting properties. The dissolution tests showed that the agglomerates obtained in presence of SLS exhibited enhanced dissolution rate while the agglomerates made in the presence of Tween 80 had no significant impact on dissolution rate of ibuprofen in comparison to untreated sample. The XRPD and DSC results showed that during the agglomeration process, ibuprofen did not undergo any polymorphic changes.
The study highlights the influence of surfactants on crystallization process leading to modified performance.


1. York P. Crystal engineering and particle design for the powder compaction process .Drug Dev Ind Pharm 1992; 18:677.
2. York P, Shekunov BYu. Crystallization processes in pharmaceutical technology and drug delivery design. J Cryst Growth 2000; 211:122-136.
3. Rasenack N, Muller B. Crystal habit and tableting behavior of ibuprofen. Int J Pharm 2002; 244:45–57.
4. Rasenack N, Muller B. Ibuprofen crystal with optimized properties. Int J Pharm 2002; 245:9–24.
5. Khan MA, Bolton S, Kislalioglu MS. Optimization of process variables for the preparation of ibuprofen coprecipitates with Eudragit S100. Int J Pharm 1994; 102:185-192.
6. Kachrimanis K, Ktistis G, Malamataris S. Crystallization conditions and physicochemical properties of ibuprofen- Eudragit†S100 spherical crystal agglomerates prepared by the solvent-change technique. Int J Pharm 1998; 173:61-74.
7. Pawar A, Paradkar A, Kadam Sh, Mahadik K. Agglomeration of Ibuprofen with Talc by Novel Crystallo-Co- Agglomeration Technique. AAPS PharmSciTech 2004; 5: Article 55.
8. Carr RL. Evaluation flow properties of solids. Chem Eng 1965; 72:163-168.
9. Carr RL. Classifying flow properties of solids. Chem Eng 1965; 72:69-72.
10. Fell JT, Newton JM. Determination of tablet strength by the diametral- compression test. J Pharm Sci 1970; 59:688–691.
11. Joiris E, Di Martino P, Berneron C, Guyot-Hermann AM, Guyot JC. Compression behavior of orthorhombic paracetamol. Pharm Res 1998; 15:1122-1130.
12. Rasenack N, Muller BW. Ibuprofen crystals with optimized properties. Int J Pharm. 2002; 245:9-24.
13. Verma S, Gokhaleb R, Burgessa DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009; 380:216–222.
14. Jbiilou M, Ettabia A, Guyot-Harmann AM, Guyot JC. Ibuprofen agglomerates preparation by phase separation. Drug Dev Ind Pharm 1999; 25:297-305.
15. Eriksson M, Alderborn G. The effect of the original particle size and tablet porosity on the increase in tensile strength during storage of sodium chloride tablets in a dry atmosphere. Int J Pharm 1995; 113:199-207.
16. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Hino T. Improved flowability and compactability of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process. Adv Powder Technol 2003; 130:283–289.
17. Nokhodchi A, Maghsoodi M, Hassan-Zadeh D, Barzegar-Jalali M. Preparation of agglomerated crystals for improving flowability and compactibility of poorly flowable and compactible drugs and excipients. Adv Powder Technol 2007; 175:73–81.
18. Maghsoodi M, Taghizadeh O, Martin GP, Nokhodchi A. Particle design of naproxen-disintegrant agglomerates for direct compression by a crystallo-co-agglomeration technique. Int J Pharm 2008; 35:45–54.
19. Szabo RP, Goczo H, PintyeHodi K, Kasajr P, Eros I , HasznosNezdei M, et al. Development of spherical crystals of an Aspartic acid salt for direct tablet making. Adv Powder Technol 2001; 114:118-24.
20. Paradkar AR, Pawar AP, Chordiya J K, Patil VB, Ketkar AR. Spherical crystallization of celecoxib. Drug Dev Ind Pharm 2002; 28:1213-1220.
21. Eriksson M, Alderborn G. The effect of particle fragmentation and deformation on the interparticulate bond formation process during powder compaction. Pharm Res 1995; 12:1031–1039.
22. Rasenack N, Muller B. Crystal habit and tableting behavior of ibuprofen. Int J Pharm 2002; 244:45–57.
23. Maheshwari M, Jahagirdar H, Paradkar A. Melt sonocrystallization of ibuprofen: Effect on crystal properties. Eur J Pharm Sci 2005; 25:41–48.
24. Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Rajabi-Siahboomi AR. Crystal habit modifications of ibuprofen and their physicomechanical characteristics. Drug Dev Ind Pharm 2001; 27:803–809.
25. El-Said Y. Effect of Co-solvents on water content and physical properties of acetaminophen crystallized from aqueous solutions. STP Pharm Sci 1995; 5:232-237.
26. Nokhodchi A, Bolourchian N, Dinarvand R. Crystal modification of phenytoin using different solvents and crystallization conditions. Int J Pharm 2003; 250:58-97.